Pooja Agarwal, PhD BioMarin Pharmaceutical Inc.

Pooja Agarwal currently serves as the Head of Therapeutic Modalities and Research and Early Development Lab Operations at BioMarin, a globally integrated genetic medicines company dedicated to translating genetic discoveries into transformative treatments. BioMarin boasts multiple approved medicines that address achondroplasia, severe hemophilia A, and various rare inherited and lysosomal storage diseases. In her role, Pooja Agarwal oversees the development of a diverse therapeutic pipeline featuring best-in-class modalities, including biologics, gene therapies, oligonucleotides, and small molecules.

Previously, Pooja led the Gene Therapy division at BioMarin for several years. Before joining BioMarin, she held the position of Senior Vice President of Research and Development at Krystal Biotech, where she played a pivotal role in the development of Vyjuvek, the first and only approved redosable topical gene therapy for Recessive Dystrophic Epidermolysis Bullosa.